Components:
Method of action:
Treatment option:
Medically reviewed by Militian Inessa Mesropovna, PharmD. Last updated on 05.04.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Top 20 medicines with the same components:
Top 20 medicines with the same treatments:
Round double-branded tablets coated with cream-white film shell, odorless or with a slight smell of ammonia.
peptic ulcer of the stomach and duodenum in the phase of exacerbation, including.h. associated with Helicobacter pylori;
chronic gastritis and gastroduodenitis in the phase of exacerbation, including.h. associated with Helicobacter pylori;
functional dispersion not related to organic diseases of the gastrointestinal tract ;
irritable bowel syndrome, occurring mainly with symptoms of diarrhea.
Inside, 30 minutes before the meal.
Adults and children over 12 years old - 1 table. 3 times a day and 1 table. for the night or 2 tablets. 2 times a day.
Children from 8 to 12 years old - 1 table. 2 times a day.
Children from 4 to 8 years old - in a dose of 8 mg / kg / day; daily dose is divided into 2 doses.
Pills should be washed down with a little water. The duration of the treatment is 4–8 weeks. Over the next 8 weeks, preparations containing bismuth should not be used. For eradaptation Helicobacter pylori it is advisable to use the vismut tricali of dicitrate in combination with other antibacterial agents with antichelicobacter activity.
The drug should not be used for more than 8 weeks. Not recommended during treatment with Novobismol® exceed established daily doses for adults and children.
During treatment, other drugs containing bismuth should not be used.
At the end of course treatment with the drug in recommended doses, the concentration of the active substance in the blood plasma does not exceed 3–5.8 μg / L, and intoxication is observed only at a concentration above 100 μg / L.
When using the drug Novobismol® coloring of feces in dark color is possible due to the formation of a sulfide of the vismut. Sometimes there is a slight darkening of the language.
individual intolerance of the drug ;
pronounced violation of the function of the kidneys ;
pregnancy;
lactation period;
childhood up to 4 years.
From the digestive system : the appearance of nausea, vomiting, more frequent stool, constipation is possible. These phenomena are not hazardous to health and are temporary.
Allergic reactions : skin rash, itching skin. For long-term use in high doses - encephalopathy associated with the accumulation of vismut in the central nervous system.
If any of the side effects specified in the description are exacerbated or any other side effects not specified in the description appear, you must inform the doctor about this.
An overdose of the drug caused by prolonged use in doses exceeding the recommended ones can lead to impaired renal function. These symptoms are completely reversible when canceling the drug Novobismol®.
Treatment: when signs of poisoning appear, the drug must be washed, activated carbon and laxative. In the future, symptomatic treatment is carried out. In case of impaired renal function, accompanied by a high level of vismut in the blood plasma, complex converters can be introduced - dimercaptoantar and dimercaptopropan sulfonic acid. In the event of a pronounced violation of the function of the kidneys, hemodialysis is shown.
Antificial agent with bactericidal activity in relation Helicobacter pylori. It also has anti-inflammatory and astringent effects. In the acidic environment of the stomach, insoluble vismuta oxychloride and citrate are precipitated, chelate compounds with a protein substrate are formed in the form of a protective film on the surface of ulcers and erosion. Increasing the synthesis of PGE, the formation of mucus and the secretion of hydrocarbonate, stimulates the activity of cytoprotectory mechanisms, increases the resistance of the gastrointestinal mucosa to the effects of pepsiin, hydrochloric acid, enzymes and bile acid salts. It leads to the accumulation of the epidermal growth factor in the defect zone. Reduces the activity of pepsin and pepsinogen.
Almost not absorbed from the LCD. It is derived mainly with feces. A small amount of vismut, received in plasma, is excreted by the kidneys.
Within half an hour before and after taking the drug Novobismol® it is not recommended to use other drugs inside (in particular antacids), as well as the use of food and liquid, in particular milk, fruits and fruit juices. This is due to the fact that they can simultaneously take inward the effectiveness of the drug Novobismol®.
- Antiseptic intestinal and astringent [Gastroprotectors]
Keep out of the reach of children.
Shelf life of the drug Novobismol®4 years.Do not apply after the expiration date indicated on the package.
Tablets coated with a film shell | 1 table. |
active substance : | |
the tricalium of dicitrate is in shape | 304.6 mg |
(in terms of Bi vismutum oxide2O3 - 120 mg) | |
auxiliary substances : corn starch - 70.6 mg; obedient K30 - 17.7 mg; potassium polyacrylate - 23.6 mg; macrogol 6000 - 6 mg; magnesium stearat - 2 mg |
Tablets coated with a film shell, 120 mg.
8 pcs. - cell contour packaging (1, 2, 3, 4, 5, 6, 7, 14, 28), cardboard packs.
10 pcs. - cell contour packaging (1, 2, 3, 4, 5, 6, 7, 12, 24), cardboard packs.
16 pcs. - cell contour packaging (1, 2, 3, 4, 5, 6, 7, 14), cardboard packs.
20 pcs. - cell contour packaging (1, 2, 3, 4, 5, 6, 7, 12), cardboard packs.
The use of the drug Novobismol® contraindicated during pregnancy. Breastfeeding should be stopped during treatment.
Uncounter.
When destroying unused packages of the drug, special precautions are not required.
Impact on the ability to drive vehicles and mechanisms. Does not affect the ability to drive a car and other mechanisms.
- K25 Vastric ulcer
- K26 Twin bowel ulcer
- K29.5 Chronic gastritis unspecified
- K29.9 Gastroduodenitis unspecified
- K30 Dispatch
- K58 Syndrome of irritable intestines
- K58.0 Syndrome of irritated intestines with diarrhea